[144] Amylyx Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amylyx Pharmaceuticals (AMLX) filed a Form 144 reporting a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $234,600, an approximate sale date of 08/12/2025, and that the shares trade on NASDAQ. The filing reports 89,167,432 shares outstanding, meaning the 30,000-share notice represents approximately 0.034% of outstanding shares.

The securities were acquired as Restricted Stock Units from the issuer on 09/30/2024 and paid on that date. The filing reports "Nothing to Report" for securities sold in the past three months. Some standard Form 144 attestation language about material nonpublic information and Rule 10b5-1 is present, while several filer and issuer identification fields in the form appear blank or not provided.

Positive

• Transaction details disclosed: broker, number of shares, aggregate market value, planned sale date, and exchange are all stated
• Acquisition clearly identified: securities were acquired as Restricted Stock Units on 09/30/2024 from the issuer
• No recent sales: filing reports "Nothing to Report" for securities sold in the past three months
• Standard attestation included: the form contains the seller's representation regarding material nonpublic information and references Rule 10b5-1 provisions

Negative

• Key identification fields missing: filer CIK/CCC and several issuer identification fields in the provided form are blank or not supplied
• Limited signer information visible: signature/date fields and explicit plan-adoption date for any 10b5-1 plan are not provided in the content
• Disclosure clarity reduced: missing issuer and filer details make independent verification harder for investors and analysts

Insights

Securities Analyst

TL;DR: Small proposed insider sale of 30,000 shares is immaterial to market capitalization; disclosure gaps limit transparency.

The Form 144 details a planned sale of 30,000 common shares valued at $234,600 through Morgan Stanley, with an approximate sale date of 08/12/2025 on NASDAQ. Against the reported 89,167,432 shares outstanding, the notice represents roughly 0.034% of the float, which is immaterial from a market-impact perspective. The filing also shows the securities were granted as Restricted Stock Units on 09/30/2024 and that there have been no sales in the prior three months. However, missing filer/issuer identifiers reduce the ease of verification for investors and analysts.

Corporate Governance Expert

TL;DR: Filing contains required attestation language and RSU details, but incomplete identification fields raise modest disclosure concerns.

The notice includes the required representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 plan adoption language. It documents acquisition as Restricted Stock Units on 09/30/2024 and shows no recent sales. From a governance and disclosure standpoint, the absence of certain filer CIK and issuer identification entries in the provided form impairs traceability and oversight, though the transaction itself appears routine and non-material.

08/12/2025 - 04:25 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	30000	234600.00	89167432	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/30/2024	Restricted Stock Units	Issuer			30000	09/30/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Amylyx (AMLX) report in this Form 144?

The filing reports a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $234,600 and an approximate sale date of 08/12/2025 on NASDAQ.

How and when were the shares acquired for this Form 144 sale?

The securities were acquired as Restricted Stock Units from the issuer on 09/30/2024, with the payment date also listed as 09/30/2024.

Does the filing show any sales by the same person in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

How large is the proposed sale relative to Amylyx's outstanding shares?

The form shows 89,167,432 shares outstanding; the 30,000-share notice represents about 0.034% of outstanding shares.

Which broker will handle the sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza 8th Floor, New York, NY 10004.

Does the filing include any attestation about material nonpublic information or 10b5-1 plans?

Yes. The standard Form 144 language includes the seller's representation that they do not know of material nonpublic information and references the option to indicate a Rule 10b5-1 plan adoption date, though a plan date is not provided in the content.